Area of research
Rheumatology · Oncology
Research interest
Research focused on Breast cancer and Sinomenine, with related work in Hazard ratio, Self-healing hydrogels, Oncology. Notable publications include 'Initial ribociclib plus endocrine therapy for HR +/ HER2 − advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study', 'Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway...', and 'Hydrogel microspheres loaded with sinomenine and Drynaria rhizome enhance the treatment of rheumatoid arthritis via immune regulation and promoting bone repair'.
Hydrogel microspheres loaded with sinomenine and Drynaria rhizome enhance the treatment of rheumatoid arthritis via immune regulation and promoting bone repair
Initial ribociclib plus endocrine therapy for <scp>HR</scp>+/<scp>HER2</scp>− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment